Is Pazopanib included in medical insurance?

Pazopanib (Pazopanib) The original drug has been approved by the State Food and Drug Administration for marketing in China, and has subsequently entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Bureau. However, reimbursement is limited to first-line treatment for patients with advanced renal cell carcinoma and patients who have received cytokine therapy for advanced renal cell carcinoma. Patients who do not meet the conditions can only purchase it at their own expense.

Pazopanib is a kinase inhibitor drug that works by slowing or preventing the spread of cancer cells. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced renal cell carcinoma (RCC, a cancer that starts in kidney cells) and advanced soft tissue sarcoma (STS) who have previously received chemotherapy. Pazopanib is an oral tablet that is generally taken once a day on an empty stomach, at least 1 hour before or 2 hours after a meal. Doctors will advise patients to take pazopanib at about the same time every day, and not to take more or less than the number of times prescribed by the doctor.

Pazopanib The price of each box of the original drug in China may be around RMB 3,000. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.